On August 20, JOINN rose 5.36% in regular trading, trading at HK$26.68/share, with turnover of HK$167 million. The stock had declined 6.39% in the previous session, and today's rebound was driven by broad-based strength across the CXO sector.

On the sector front, Life Sciences Tools & Services names rallied collectively, with GENSCRIPT BIO surging 16.89%, WUXI BIO gaining 6.05%, WUXI APPTEC up 4.75%, XTALPI rising 14.11%, and INSILICO climbing 11.72%. The sector linkage provided strong upward momentum for JOINN's recovery.

On the fundamental side, the company disclosed in-hand orders of RMB 3.1 billion as of Q1-end, with legacy low-price orders being cleared in an orderly manner and non-human primate pricing recovering. JOINN is scheduled to hold a board meeting on August 28 to review interim results. A prior earnings pre-announcement indicated H1 net profit attributable to shareholders is expected to surge 884.9% to 1,377.4% year-over-year, with biological asset fair value gains serving as the core driver. Market participants are positioning ahead of the formal results release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)